癌症进展
癌癥進展
암증진전
Oncology Progress
2015年
5期
541-544
,共4页
乳腺癌%类更年期%他莫昔芬%中药
乳腺癌%類更年期%他莫昔芬%中藥
유선암%류경년기%타막석분%중약
breast cancer%menopausal-like%tamoxifen%traditional Chinese medicine
目的：探讨黑逍遥散联合肾四味对他莫昔芬治疗乳腺癌所致类更年期症状患者的影响。方法使用随机数字表法将60例乳腺癌伴类更年期症状的患者分为对照组和观察组，每组各30例。对照组患者接受内分泌治疗及口服维生素B1、B6、谷维素，观察组患者接受内分泌治疗及黑逍遥散及肾四味加减。持续治疗4个月后对比两组患者治疗前、治疗2个月和治疗4个月时的性激素水平（雌二醇、卵泡刺激素、垂体泌乳素、黄体生成素）、血清肿瘤标志物（CA15-3和CA125）水平及治疗前后的生活质量。结果两组患者各观察时点的性激素水平及血清肿瘤标志物水平差异均无统计学意义（P＞0.05）。治疗后，观察组与对照组的总体健康状况评分（80.15±8.96 vs 45.69±11.24）、功能评分（55.25±11.78 vs 36.85±10.29）、症状及经济状态评分（40.14±17.58 vs 65.87±12.96）相比，观察组均优于对照组，差异具有统计学意义（P＜0.05）。结论黑逍遥散联合肾四味可有效改善经他莫昔芬治疗后伴有类更年期乳腺癌患者的生活质量，对其性激素及肿瘤标志物水平并无影响。
目的：探討黑逍遙散聯閤腎四味對他莫昔芬治療乳腺癌所緻類更年期癥狀患者的影響。方法使用隨機數字錶法將60例乳腺癌伴類更年期癥狀的患者分為對照組和觀察組，每組各30例。對照組患者接受內分泌治療及口服維生素B1、B6、穀維素，觀察組患者接受內分泌治療及黑逍遙散及腎四味加減。持續治療4箇月後對比兩組患者治療前、治療2箇月和治療4箇月時的性激素水平（雌二醇、卵泡刺激素、垂體泌乳素、黃體生成素）、血清腫瘤標誌物（CA15-3和CA125）水平及治療前後的生活質量。結果兩組患者各觀察時點的性激素水平及血清腫瘤標誌物水平差異均無統計學意義（P＞0.05）。治療後，觀察組與對照組的總體健康狀況評分（80.15±8.96 vs 45.69±11.24）、功能評分（55.25±11.78 vs 36.85±10.29）、癥狀及經濟狀態評分（40.14±17.58 vs 65.87±12.96）相比，觀察組均優于對照組，差異具有統計學意義（P＜0.05）。結論黑逍遙散聯閤腎四味可有效改善經他莫昔芬治療後伴有類更年期乳腺癌患者的生活質量，對其性激素及腫瘤標誌物水平併無影響。
목적：탐토흑소요산연합신사미대타막석분치료유선암소치류경년기증상환자적영향。방법사용수궤수자표법장60례유선암반류경년기증상적환자분위대조조화관찰조，매조각30례。대조조환자접수내분비치료급구복유생소B1、B6、곡유소，관찰조환자접수내분비치료급흑소요산급신사미가감。지속치료4개월후대비량조환자치료전、치료2개월화치료4개월시적성격소수평（자이순、란포자격소、수체비유소、황체생성소）、혈청종류표지물（CA15-3화CA125）수평급치료전후적생활질량。결과량조환자각관찰시점적성격소수평급혈청종류표지물수평차이균무통계학의의（P＞0.05）。치료후，관찰조여대조조적총체건강상황평분（80.15±8.96 vs 45.69±11.24）、공능평분（55.25±11.78 vs 36.85±10.29）、증상급경제상태평분（40.14±17.58 vs 65.87±12.96）상비，관찰조균우우대조조，차이구유통계학의의（P＜0.05）。결론흑소요산연합신사미가유효개선경타막석분치료후반유류경년기유선암환자적생활질량，대기성격소급종류표지물수평병무영향。
Objective To study the clinical efficacy of Heixiaoyao San in breast cancer patients with menopausal-like symptoms induced by tamoxifen treatment. Method 60 cases of breast cancer patients with menopausal-like symptoms were included in this study and were randomized into control group and observation group, with 30 cases in each. The patients of control group were given oral vitamin B1, B6 and oryzanol, while observation group was ad-ministered with Chinese medicine of Heixiaoyao San combined with Shensiwei, the estrogen levels (estradiol, follicle stimulating hormone, pituitary prolactin, luteinizing hormone) and serum tumor markers (CA15-3, CA125), as well as quality of life were measured before treatment, and after 2-month and 4-month treatment. Result The levels of all estrogen levels at each time point of both groups were similar (P> 0.05). As for the quality of life, the overall health status score (80.15±8.96 vs 45.69±11.24), function score (55.25±11.78 vs 36.85±10.29), symptoms and financial bur-den score (55.25 ± 11.78 vs 36.85 ± 10.29) were all higher in the observation group compared with the control group, and the differences were statistically significant (P < 0.05). Conclusion Heixiaoyao San combined with Shensiwei effectively improves the quality of life for breast cancer patients with menopausal-like symptoms, but has no influ-ence on levels of estrogen and tumor markers.
